Crossmark Global Holdings Inc. Takes Position in STAAR Surgical (NASDAQ:STAA)

Crossmark Global Holdings Inc. purchased a new position in STAAR Surgical (NASDAQ:STAA) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 11,016 shares of the medical instruments supplier’s stock, valued at approximately $409,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Arcadia Investment Management Corp MI acquired a new position in shares of STAAR Surgical in the 3rd quarter worth approximately $37,000. Covestor Ltd lifted its stake in STAAR Surgical by 38.9% during the first quarter. Covestor Ltd now owns 2,690 shares of the medical instruments supplier’s stock worth $103,000 after purchasing an additional 754 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in STAAR Surgical in the second quarter worth $129,000. Van ECK Associates Corp increased its stake in STAAR Surgical by 12.7% during the third quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after purchasing an additional 393 shares during the last quarter. Finally, Larson Financial Group LLC acquired a new stake in shares of STAAR Surgical during the second quarter worth $130,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Trading Down 2.3 %

Shares of NASDAQ:STAA opened at $26.66 on Friday. The firm’s 50 day moving average is $31.29 and its two-hundred day moving average is $37.28. The firm has a market capitalization of $1.31 billion, a P/E ratio of 60.59 and a beta of 0.61. STAAR Surgical has a 52 week low of $26.62 and a 52 week high of $52.68.

Analysts Set New Price Targets

STAA has been the subject of several research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a report on Thursday, October 31st. Canaccord Genuity Group lowered their target price on STAAR Surgical from $41.00 to $31.00 and set a “hold” rating for the company in a report on Friday, November 1st. Finally, Stifel Nicolaus dropped their price target on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, August 26th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $43.33.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.